Matthew Lumley
Venture Partner
Matthew is a Venture Partner in the Medicxi investment team. Alongside his role at Medicxi, Matthew is CEO of Myosana Therapeutics. Prior to joining Medicxi, Matthew was global clinical lead for Moderna's first mRNA therapeutics in Rare Disease. He has also worked in medical affairs and market access roles at Pfizer.
Matthew received his medical degree from Imperial College London and PhD in Cardiovascular Physiology from Kings College London. He is a full member of the Royal College of Physicians (MRCP) and is a member of the Faculty of Pharmaceutical Medicine (MFPM).
